Xing Qiu

511 total citations
16 papers, 395 citations indexed

About

Xing Qiu is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Xing Qiu has authored 16 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Hematology. Recurrent topics in Xing Qiu's work include Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Xing Qiu is often cited by papers focused on Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Xing Qiu collaborates with scholars based in China, United States and Germany. Xing Qiu's co-authors include Xiaobao Yang, Biao Jiang, Ning Sun, Ying Kong, Hui Zhong, Xiaoling Song, Yan Li, Chaowei Ren, Haixia Liu and Jinju Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Xing Qiu

14 papers receiving 391 citations

Peers

Xing Qiu

ONCOL

HEMAT

PRM

Michael J. Bond United States

Chelsea E. Powell United States

Frédéric Féru United States

Shenxin Zeng China

Caterina Ferraro United States

Inchul You United States

Chaowei Ren China

Jason Marineau United States

Aleša Bricelj Slovenia

Tomoko Asatsuma‐Okumura Japan

Michael J. Bond United States

Xing Qiu

458 ×1.3

227 ×1.3

ONCOL

101 ×0.8

HEMAT

22 ×0.7

PRM

33 ×1.1

Citations per year, relative to Xing Qiu Xing Qiu (= 1×) peers Michael J. Bond

Countries citing papers authored by Xing Qiu

Since Specialization

Citations

This map shows the geographic impact of Xing Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xing Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xing Qiu more than expected).

Fields of papers citing papers by Xing Qiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xing Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xing Qiu. The network helps show where Xing Qiu may publish in the future.

Co-authorship network of co-authors of Xing Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Xing Qiu. A scholar is included among the top collaborators of Xing Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xing Qiu. Xing Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Lee, Heng‐Huan, Violetta V. Leshchenko, Ravi Prakash Shukla, et al.. (2025). SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Blood Advances. 9(24). 6267–6278.

Hosseini, Amir, Xing Qiu, Yan Xiong, et al.. (2025). Discovery of an LSD1 PROTAC degrader. Proceedings of the National Academy of Sciences. 122(20). e2425812122–e2425812122. 4 indexed citations

Zhu, Zhichuan, He Chen, Xing Qiu, et al.. (2025). (GGAA)₃-Based TF-PROTACs Enable Targeted Degradation of ETV6 to Inhibit Ewing Sarcoma Growth. Journal of the American Chemical Society. 147(16). 13396–13404.

Luo, Chen‐Hui, Lihong Hu, Xia Li, et al.. (2024). CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma. Nature Communications. 15(1). 10594–10594. 2 indexed citations

Wang, Zhen, Dingpeng Zhang, Xing Qiu, et al.. (2024). Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1. Journal of the American Chemical Society. 146(11). 7584–7593. 20 indexed citations

Wang, Zhen, Jing Liu, He Chen, et al.. (2023). Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins. Journal of the American Chemical Society. 145(19). 10872–10879. 19 indexed citations

Provasi, Davide, Xing Qiu, H. Ümit Kanıskan, et al.. (2023). De Novo Design of κ-Opioid Receptor Antagonists Using a Generative Deep-Learning Framework. Journal of Chemical Information and Modeling. 63(16). 5056–5065. 10 indexed citations

Wang, Zhen, Jing Liu, Xing Qiu, et al.. (2023). Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2. Journal of the American Chemical Society. 145(40). 21871–21878. 9 indexed citations

Sun, Renhong, Haixia Liu, Chaowei Ren, et al.. (2022). Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators. European Journal of Medicinal Chemistry. 247. 115016–115016. 3 indexed citations

10.

Marcellino, Bridget K., Xiaobao Yang, H. Ümit Kanıskan, et al.. (2022). An MDM2 degrader for treatment of acute leukemias. Leukemia. 37(2). 370–378. 18 indexed citations

11.

Liu, Haixia, Xiaoling Song, Ning Sun, et al.. (2021). Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems. European Journal of Medicinal Chemistry. 218. 113328–113328. 84 indexed citations

12.

Liu, Haixia, Xinyu Ding, Linyi Liu, et al.. (2021). Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry. 223. 113645–113645. 42 indexed citations

13.

Ren, Chaowei, Ning Sun, Haixia Liu, et al.. (2021). Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. Journal of Medicinal Chemistry. 64(13). 9152–9165. 32 indexed citations

14.

Sun, Ning, Chaowei Ren, Ying Kong, et al.. (2020). Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. European Journal of Medicinal Chemistry. 193. 112190–112190. 66 indexed citations

15.

Liu, Haixia, Renhong Sun, Chaowei Ren, et al.. (2020). Construction of an IMiD-based azide library as a kit for PROTAC research. Organic & Biomolecular Chemistry. 19(1). 166–170. 24 indexed citations

16.

Qiu, Xing, Ning Sun, Ying Kong, et al.. (2019). Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. Organic Letters. 21(10). 3838–3841. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact